10 companies selected for Life Sciences Start-up Day

The goal of the Life Sciences Start-up Day is to bring together business angels, investors, start-up mentors and entrepreneurs. The day will start with an “Angelday” – an interactive workshop for people wanting to invest in start-ups. This session focuses on some of the situations faced by business angels investing in medical technology or biotech and how to evaluate projects and perform due diligence. The course will include subjects such as determinants for value, due diligence processes, interpersonal relationships. It will focus on practical implications, three cases studies (Anteis, Endosense, Endoart) are included in the program. Speakers are Pierre Strubin, Fongit, Diego Braguglia, VI Partners, Davide Mauri, Polytech Ventures, and Ruedi Gygax, Biobac and Nextech Invest.

The Angelday will be followed by a pitching session with ten start-ups looking for investors. The names of the ten selected start-ups were announces recently. They are:

Amal Therapeutics is a privately-held Swiss start-up company, spin-off of the University of Geneva. Its mission is to develop and progress novel therapeutic cancer vaccines with a proprietary family of vectors fused to rationally designed chimeric proteins.

ArisGen provides effective modes of delivery for small molecules, peptides, and siRNA therapeutics to deliver their full therapeutic potential to patients. The company has developed novel, fully independent IP to provide effective solutions to deliver drugs, from mode of administration to target.

Léman Micro Devices is developing an inexpensive, miniature sensor module that can be integrated into conventional smartphones, tablets and other mobile devices. The start-up plans to provide cloud-based services for the data transfer of measured values to healthcare providers, clinics and research institutions.

Nanolive has developed a disruptive proprietary technology, which allows for the very first time to explore a living cell in 3D without damaging it. By experiencing the living cell in a completely new way, Nanolive’s 3D Cell-Explorer shows a comprehensive representation in color of its activity.

By generating neural tissues and disease models from human or murine pluripotent stem cells, NEURIX offers alternatives to traditional R&D in the central nervous system. NEURIX provides researchers with customized services including MiniBrains, an innovative in vitro neural tissue in 3D.

Founded in 2009, Obexia is a privately held biopharmaceuticals start-up company based in Basel. Obexia focuses on the development of breakthrough therapies for cachexia & anorexia conditions to improve people’s lives.

One Drop Diagnostics has developed a mobile medical diagnostics device that provides rapid, accurate and sensitive diagnostics of multiple biomarkers from one drop of blood in a low cost, handheld format.

PB&B is developing four types of injections of biodegradable microspheres to render Aesthetics procedures non-surgical; their effect mimics normal physiological processes as to achieve: (i) Temporary Breast Enhancement (ii) Permanent Breast Enhancement (iii) Buttock enhancement (iv) Facial rejuvenation

SamanTree Technologies is a Swiss, biomedical instrumentation startup that develops and commercializes a new generation of imaging systems for in-vitro and in-vivo histology for medical and diagnostic devices.

Sophia Genetics offers health professionals who perform clinical genetic testing an Integrated Clinical Dry Lab Service supporting the bioinformatic analysis, quality assurance, visualisation and banking of patient DNA sequence data generated by Next Generation Sequencing (NGS).

Last part of the day will be a panel discussion with Nicolas Durand, Founder at Abionic,  Jean-Pierre Rosat, CEO at Aleva Neurotherapeutics, Jean-Marc Wismer,  CEO Sensimed; Nikos Stergiopoulos, co-founder Endoart and  Antlia, Vitali Verin , co-founder Endosense.

The Day will take place at the new Geneva Biotech Campus. More information on a dedicated website.